Previous 10 | Next 10 |
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax Technologies (NASDAQ:DVAX) CpG 1018 advanc...
Sinovac Biotech (NASDAQ:SVA) said on Sunday that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The vaccine is administered intramuscula...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC Corona...
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization (WHO) prequalification for its Poliomyelitis Vaccine (Vero Cell, Inact...
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (“SEC”) under the H...
Sinovac Biotech press release (NASDAQ:SVA): FY GAAP EPS of $74.27. Revenue of $19.4B (+3699.5% Y/Y). Non-GAAP adjusted EBITDA was $17.6B in 2021, compared to $229.9M in the prior year. As of December 31, 2021, cash and cash equivalents and restricted cash totaled $11.6B, compared to $1.1B as ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. Th...
Sinovac Biotech's (NASDAQ:SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong. Sinovac, a unit of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY), said preclinical studies showed that the SINOVAC Omicron variant inactivated vaccine was safe and eff...
A group of global institutions led by the International Monetary Fund (IMF) has proposed $15 billion in grants this year and $10 billion annually thereafter as part of a global strategy to address the long-term risks of COVID-19. The IMF, in partnership with the Coalition for Epidemic Prepare...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...